FcRn anticorps

N° du produit ABIN1774762

Détail du produit anti-FcRn anticorps

Highlights:

• Anticorps FcRn de haute qualité (Clone ADM31) pour la détection de FcRn.
• Hautement spécifique pour le FcRn humain, bloque la liaison de l'albumine sérique humaine.
• PBS-only, preservative free
• 15 références PubMed disponibles pour cet anticorps FcRn.

Antigène: FcRn (IgG receptor FcRn (FcRn))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp FcRn est non-conjugé

Application: ELISA, Immunofluorescence (IF), Flow Cytometry (FACS), Cell-ELISA (cELISA), Functional Studies (Func)

Attributs du produit: based on recognition of the complete native protein expressed on transfected mammalian cells

Purification: Purified, Protein G

Immunogène: hFcRn

Clone: ADM31

Isotype: IgG2b lambda

Informations sur le produit:

À quoi peut servir l'anticorps anti-FcRn ABIN1774762 / ADM31 ? Cet anticorps monoclonal de souris anti-FcRn n'est pas conjugué et convient à la détection du FcRn (récepteur Fc) dans des échantillons humains. L'anticorps FcRn est validé pour Cell ELISA, ELISA, FACS et IF.

Quelles sont les données de validation disponibles pour cet anticorps FcRn / anticorps ADM31 ? 6 images pour FACS et autres applications sont disponibles. Le produit est cité dans 15 publications PubMed. Utilisez notre produit de haute qualité pour détecter de manière fiable le récepteur Fc.

Le récepteur Fc de type CMH de classe I (FcRn) fonctionne comme un récepteur de trafic intracellulaire, uniquement responsable de la prolongation de la demi-vie sérique des anticorps de sous-classe IgG et de la facilitation de leur passage à travers les barrières cellulaires. Par ces actions, le FcRn a un impact significatif sur divers aspects de la biologie des anticorps et de la pathobiologie. Son rôle crucial dans la régulation de la pharmacocinétique des IgG a été exploité dans le développement d'anticorps thérapeutiques et de traitements biologiques connexes. En outre, le FcRn est impliqué dans le transport de l'albumine sérique, ce qui contribue à l'amélioration des caractéristiques pharmacocinétiques des thérapies conjuguées à l'albumine. Cependant, le manque d'outils sérologiques fiables ciblant le FcRn humain a limité la compréhension de ses fonctions et de ses utilisations thérapeutiques potentielles.

Information d'application

Indications d'application:

• Flow cytometry: 1.2 μg/10^6 cells
• ELISA: 1:200 - 1:400
• CELISA: 1:200 - 1:400

For each application a titration should be performed to determine the optimal concentration.

Restrictions: For Research Use only

Stockage

Buffer: PBS pH 7.2

Conseil sur la manipulation: avoid repeated freezing and thawing

Stock: 4 °C

Références pour anticorps anti-FcRn (ABIN1774762)

Gjølberg, Frick, Mester, Foss, Grevys, Høydahl, Jørstad, Schlothauer, Sandlie, Moe, Andersen: "Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life." dans: Communications biology, Vol. 5, Issue 1, pp. 832, (2022) (PubMed).

Cines, Zaitsev, Rauova, Rux, Stepanova, Krishnaswamy, Sarkar, Kowalska, Zhao, Mast, Blumberg, McCrae, Poncz, Hubbard, Pyzik, Blumberg: "FcRn augments induction of tissue factor activity by IgG-containing immune complexes." dans: Blood, Vol. 135, Issue 23, pp. 2085-2093, (2021) (PubMed).

Hubbard, Pyzik, Rath, Kozicky, Sand, Gandhi, Grevys, Foss, Menzies, Glickman, Fiebiger, Roopenian, Sandlie, Andersen, Sly, Baker, Blumberg: "FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity." dans: The Journal of experimental medicine, Vol. 217, Issue 10, (2021) (PubMed).

Bern, Nilsen, Ferrarese, Sand, Gjølberg, Lode, Davidson, Camire, Bækkevold, Foss, Grevys, Dalhus, Wilson, Høydahl, Christianson, Roopenian, Schlothauer, Michaelsen, Moe, Lombardi, Pinotti, Sandlie et al.: "An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. ..." dans: Science translational medicine, Vol. 12, Issue 565, (2021) (PubMed).

Casulleras, Flores-Costa, Duran-Güell, Alcaraz-Quiles, Sanz, Titos, López-Vicario, Fernández, Horrillo, Costa, de la Grange, Moreau, Arroyo, Clària: "Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis." dans: Science translational medicine, Vol. 12, Issue 566, (2021) (PubMed).

Blumberg, Humphries, Jones, Pearce, Holgate, Hearn, Cheung, Mahmood, Del Tito, Graydon, Stolz, Bitonti, Purohit, de Graaf, Kacena, Andersen, Christianson, Roopenian, Hubbard, Gandhi, Lasseter, Pyzik et al.: "Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. ..." dans: Science advances, Vol. 5, Issue 12, pp. eaax9586, (2020) (PubMed).

Chung, Nguyen, Lin, Lafrance-Vanasse, Scales, Lin, Deng, Williams, Sperinde, Li, Zheng, Sukumaran, Tesar, Ernst, Fischer, Lazar, Prabhu, Song: "An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans." dans: mAbs, Vol. 11, Issue 5, pp. 942-955, (2019) (PubMed).

Swiercz, Mo, Khare, Schneider, Ober, Ward: "Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption." dans: Oncotarget, Vol. 8, Issue 2, pp. 3528-3541, (2018) (PubMed).

Pyzik, Rath, Kuo, Win, Baker, Hubbard, Grenha, Gandhi, Krämer, Mezo, Taylor, McDonnell, Nienaber, Andersen, Mizoguchi, Blumberg, Purohit, Jones, Christianson, Lencer, Sandlie, Kaplowitz, Roopenian et al.: "Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. ..." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, Issue 14, pp. E2862-E2871, (2018) (PubMed).

Grevys, Nilsen, Sand, Daba, Øynebråten, Bern, McAdam, Foss, Schlothauer, Michaelsen, Christianson, Roopenian, Blumberg, Sandlie, Andersen: "A human endothelial cell-based recycling assay for screening of FcRn targeted molecules." dans: Nature communications, Vol. 9, Issue 1, pp. 621, (2018) (PubMed).

Roopenian, Christianson, Proetzel, Sproule: "Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies." dans: Methods in molecular biology (Clifton, N.J.), Vol. 1438, pp. 103-14, (2017) (PubMed).

Foss, Grevys, Sand, Bern, Blundell, Michaelsen, Pleass, Sandlie, Andersen: "Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization." dans: Journal of controlled release : official journal of the Controlled Release Society, Vol. 223, pp. 42-52, (2016) (PubMed).

Christianson, Sun, Akilesh, Pesavento, Proetzel, Roopenian: "Monoclonal antibodies directed against human FcRn and their applications." dans: mAbs, Vol. 4, Issue 2, pp. 208-16, (2014) (PubMed).

Powner, McKenzie, Christianson, Roopenian, Fruttiger: "Expression of neonatal Fc receptor in the eye." dans: Investigative ophthalmology & visual science, Vol. 55, Issue 3, pp. 1607-15, (2014) (PubMed).

Sand, Dalhus, Christianson, Bern, Foss, Cameron, Sleep, Bjørås, Roopenian, Sandlie, Andersen: "Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies." dans: The Journal of biological chemistry, Vol. 289, Issue 24, pp. 17228-39, (2014) (PubMed).

Détails sur FcRn

Antigène: FcRn (IgG receptor FcRn (FcRn))

Abstract: FcRn Produits

Synonymes: anticorps FCRN, anticorps alpha-chain, anticorps FcRn, anticorps Fc fragment of IgG receptor and transporter, anticorps Fc receptor, IgG, alpha chain transporter, anticorps FCGRT, anticorps Fcgrt

Sujet: The MHC class I-like Fc receptor (FcRn) is an intracellular trafficking Fc receptor that is uniquely responsible for the extended serum half-life of antibodies of the IgG subclass and their ability to transport across cellular barriers. By performing these functions, FcRn affects numerous facets of antibody biology and pathobiology. Its critical role in controlling IgG pharmacokinetics has been leveraged for the design of therapeutic antibodies and related biologics. FcRn also traffics serum albumin and is responsible for the enhanced pharmacokinetic properties of albumin-conjugated therapeutics.
Synonyms: IgG receptor FcRn large subunit p51, Neonatal Fc receptor, FCGRT

UniProt: P55899

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process